BuzzSparks.org

Achaogen


Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company’s most advanced drug candidate, ACHN-490, has...

Founded in 2004
Homepage:
Total money raised: $100.9M

Headquarters

94080 7000 Shoreline Court
Suite 371

South San Francisco
USA CA
Updated on Jun 14, 2013
Achaogen at CrunchBase
Tags:   anti   anti-bacteria   bacteria   biopharma

Bryan E. Roberts Chairman, Board of Directors
Kenneth Hillan Chief Medical Officer, Chief Executive Officer, Board of Directors
Dennis Hom VP Finance & Corporate Development
Becki Filice Senior Vice President, Development Operations and Portfolio Management, Vice President, Development Operations and Portfolio Management
Christine Murray Vice President, Regulatory Affairs
Christopher T. Walsh Board of Directors
Kush Parmar Boards
Robert J. More Board of Directors
Kush Parmar Board Observer
Past

March, 2013

Achaogen raised $18.9M in partial round

SEC    sec.gov

August, 2010

Achaogen Awarded Contract Worth up to $64 Million by BARDA for the Development of ACHN-490    achaogen.com

April, 2010

Achaogen raised $56M in a Series C round from Frazier Healthcare Ventures, Alta Partners, 5AM Ventures, ARCH Venture Partners, Domain Associates, Venrock, and Wellcome Trust

Achaogen Completes $56 Million Series C Financing    pr-inside.com

October, 2006

Achaogen raised $26M in a Series B round from Domain Associates, 5AM Ventures, ARCH Venture Partners, Venrock, and Versant Ventures

Achaogen Closes Series B Financing    achaogen.com

2004

Achaogen was founded in 2004